Capricor Therapeutics, Inc. (CAPR) vs Editas Medicine, Inc. (EDIT)

A side-by-side comparison of Capricor Therapeutics, Inc. and Editas Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CAPR vs EDIT

growth of $100 · dividends reinvested · last 10y
CAPR -76.9% (-13.6%/yr)EDIT -81.4% (-15.5%/yr)CAPR compounded faster over this window
0200400600Start $10020182020202220242026$23$19
CAPR EDIT

CAPR vs EDIT: by the numbers

  • •CAPR is the larger company ($435M vs $432M market cap).
  • •Both run net losses; CAPR's is the smaller (0.00% vs -157.32% net margin).

Metrics side by side

Valuation

MetricCAPREDIT
P/S ratioN/A9.19
P/B ratio1.774.10
EV / EBITDA0.43N/A

Profitability

MetricCAPREDIT
Gross margin0.00%100.00%
Operating margin0.00%-245.15%
Net margin0.00%-157.32%
ROE-52.56%-70.24%
ROIC-40.25%-48.61%

Growth (annualized)

MetricCAPREDIT
Revenue CAGR (5Y)N/A-10.34%
Total return CAGR (5Y)15.17%-40.76%

Frequently asked

How have CAPR and EDIT total returns compared?
Over the past 10 years, CAPR delivered -13.84% and EDIT delivered -15.75% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.